# Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

> **NCT05078866** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Colorectal Carcinoma
- Lynch Syndrome

## Interventions

- **BIOLOGICAL:** Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Endoscopic Biopsy
- **BIOLOGICAL:** MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05078866
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-10
- **Primary completion:** 2025-04-16
- **Final completion:** 2026-09-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05078866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05078866, "Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05078866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*